Crystalline forms of N-{[(S)-{[3-(4-chlorphenyl)-4-phenyl-4, 5-dihydro-1h-pyrazol-1-yl] [4-(trifluoromethyl) benzenesulfonamido] methylene} amino] imino} acetamide
By developing CB1 receptor inhibitor compounds targeting surrounding tissues, the problem of the existence of neural side effects of existing CB1 receptor inhibitors is solved, and effective treatment of metabolic syndrome is achieved while reducing the risk of side effects.
Patent Information
- Application Number
- CN202380020969.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-09
- Filing Date
- 2023-02-08
- Publication Date
- 2024-11-26
AI Technical Summary
Existing CB1 receptor inhibitors used in the treatment of obesity and metabolic syndrome have neuropsychiatric side effects, leading to their market exit, and it is difficult to avoid interaction with brain tissue, resulting in side effects.
Develop a compound N-{[(S)-{[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-yl][4-(Triple Fluoromethyl)benzenesulfonamide]methylene}amino}imibomyl}acetamide, a stable crystalline form of the acetamide, reduces nerve side effects by targeting surrounding tissue without interacting with brain tissue.
The stable crystalline form of this compound effectively inhibits CB1 receptors, reduces appetite and lipid storage, improves metabolic disorders, and reduces the risk of neuropsychiatric side effects due to its targeted design.
Smart Images

Figure CN119032082A_ABST
Abstract
Description
Technical Field
[0001] The technical field relates to crystalline forms of the compound N-N'-((S)-3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(((4-(trifluoromethyl)phenyl)sulfonyl)imino)methyl)carbamimidyl)acetamide, and pharmaceutical compositions, therapeutic uses and preparation methods thereof. Background Art
[0002] It is well known that activation of the cannabinoid CB1 receptor increases appetite, increases lipid biosynthesis and storage, inhibits the effects of insulin and leptin, and promotes inflammation and fibrosis. Therefore, research has focused on developing CB1 receptor inhibitors for potential treatment of obesity and its associated metabolic disorders (called metabolic syndrome). Rimonabant has been shown to be effective in treating metabolic syndrome, but causes neuropsychiatric (i.e., CNS-related) side effects, which led to its withdrawal from the market.
[0003] George Kunos et al. in U.S. Pat. No. 9,765,031 disclose compounds that preferentially target CB1 receptors in peripheral tissues (e.g., adipose tissue, liver, muscle, lung, kidney, macrophages, pancreatic β cells, and gastrointestinal tract) without interacting with CB1 receptors in brain tissue, thereby avoiding or reducing CNS-related side effects.
[0004] One of the compounds is N-{[(S)-{[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl][4-(trifluoromethyl)benzenesulfonamido]methylene}amino]carbamoyl}acetamide, and it is desirable to identify a stable crystalline form thereof that may be suitable for therapeutic use. Summary of the invention
[0005] In one aspect, compounds of formula I are provided:
[0006]
[0007] It is crystalline and exhibits an X-ray powder diffraction (XRPD) pattern having characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 6.46, 15.88, 19.44 and 5.86.
[0008] In some embodiments, the XRPD pattern further has characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 7.46, 22.15, and 26.24.
[0009] In some embodiments, the XRPD pattern further has characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 9.85, 19.07, 22.77.
[0010] In some embodiments, the XRPD pattern further has characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 3.81, 17.17, and 20.84.
[0011] In some embodiments, the XRPD pattern further has characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 17.95, 15.43, and 24.24.
[0012] In another aspect, there is provided a compound of formula I:
[0013]
[0014] It is crystalline, and its differential scanning calorimetry (DSC) thermogram shows an endotherm with an onset at about 157.1 °C.
[0015] In another aspect, there is provided a compound of formula I:
[0016]
[0017]
[0018] It is crystalline, and its differential scanning calorimetry (DSC) thermogram shows an endotherm with a peak temperature of about 167.9°C.
[0019] In another aspect, there is provided a compound of formula I:
[0020]
[0021] Its X-ray powder diffraction pattern is Figure 4A - Form C is substantially the same.
[0022] In another aspect, there is provided a compound of formula I:
[0023]
[0024] It is crystalline and exhibits an X-ray powder diffraction (XRPD) pattern having characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 5.89 and 17.39.
[0025] In some embodiments, the XRPD pattern further has characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 9.39 and 17.80.
[0026] In some embodiments, the XRPD pattern further has a characteristic peak expressed in degrees 2Θ (± 0.2° 2Θ) at 12.96.
[0027] In some embodiments, the XRPD pattern further has a characteristic peak expressed in degrees 2Θ (± 0.2° 2Θ) at 19.85.
[0028] In some embodiments, the XRPD pattern further has a characteristic peak expressed in degrees 2Θ (± 0.2° 2Θ) at 16.96.
[0029] In another aspect, there is provided a compound of formula I:
[0030]
[0031] It is crystalline, and its differential scanning calorimetry (DSC) thermogram shows an endotherm with an onset at about 152.2°C.
[0032] In another aspect, there is provided a compound of formula I:
[0033]
[0034] It is crystalline, and its differential scanning calorimetry (DSC) thermogram shows an endotherm with a peak temperature of about 162.3°C.
[0035] In another aspect, there is provided a compound of formula I:
[0036]
[0037] Its X-ray powder diffraction pattern is Figure 2A Shown are essentially the same.
[0038] In some embodiments, the compound of Formula I comprises a crystalline form that is 95% pure or greater.
[0039] In some embodiments, the purity is 99% or greater.
[0040] In some embodiments, the purity is 99.8% or greater.
[0041] In some embodiments, the compound of Formula I is substantially pure.
[0042] In another aspect, a pharmaceutical composition is provided, which comprises a compound of Formula I as described herein, and a pharmaceutically acceptable carrier or excipient.
[0043] In some embodiments, the pharmaceutical composition is formulated as an oral dosage form.
[0044] In some embodiments, the oral dosage form is a tablet, capsule, lozenge, pastille, or granules.
[0045] In some embodiments, the pharmaceutical composition is formulated as an oral suspension.
[0046] In another aspect, provided is the use of a compound of formula I as described herein or a pharmaceutical composition as described herein for treating a disease or condition selected from the group consisting of obesity (type 1 or type 2), nonalcoholic and alcoholic fatty liver disease (risk factor for insulin resistance), comorbidity of obesity, comorbidity of diabetes, Prader-Willi syndrome (PWS), proopiomelanocortin (POMC) deficiency obesity, LepR deficiency obesity, POMC heterozygous deficiency obesity, POMC epigenetic disorders, Bardet-Biedl syndrome, syndrome, dyslipidemia that predisposes to the development of atherosclerotic heart disease, diabetic nephropathy, fibrosis and fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and Hermansky-Pudlak syndrome pulmonary fibrosis (HPS-PF), and gout.
[0047] In another aspect, provided is the use of a compound of formula I as described herein or a pharmaceutical composition as described herein for the preparation of a medicament for treating a disease or condition selected from the group consisting of obesity (type 1 or type 2), nonalcoholic and alcoholic fatty liver disease (risk factor for insulin resistance), comorbidities of obesity, comorbidities of diabetes, Prader-Willi syndrome (PWS), proopiomelanocortin (POMC) deficiency obesity, LepR deficiency obesity, POMC heterozygous deficiency obesity, POMC epigenetic disorders, Bardet-Biedl syndrome, syndrome, dyslipidemia that predisposes to the development of atherosclerotic heart disease, diabetic nephropathy, fibrosis and fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and Hermansky-Pudlak syndrome pulmonary fibrosis (HPS-PF), and gout.
[0048] In another aspect, a method of treating a disease or condition selected from the group consisting of obesity, diabetes (type 1 or type 2), nonalcoholic and alcoholic fatty liver disease (risk factor for insulin resistance), comorbidities of obesity, comorbidities of diabetes, Prader-Willi syndrome (PWS), pro-opiomelanocortin (POMC) deficiency obesity, LepR deficiency obesity, POMC heterozygous deficiency obesity, POMC epigenetic disorders, Bardet-Biedl syndrome, syndrome, dyslipidemia that is susceptible to the development of arteriosclerotic heart disease, diabetic nephropathy, fibrosis and fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF) and Hermansky-Pudlak syndrome pulmonary fibrosis (HPS-PF), and gout, the method comprising administering to a subject in need thereof a compound of formula I as defined herein or a pharmaceutical composition as defined herein.
[0049] In some embodiments, the comorbidity of obesity is selected from metabolic syndrome, dementia, heart disease, hypertension, gallbladder disease, gastrointestinal disorders, menstrual disorders, degenerative arthritis, venous stasis ulcers, hypoventilation syndrome, sleep apnea, snoring, coronary artery disease, arteriosclerotic disease, pseudotumor cerebri, osteoarthritis, high cholesterol, and increased incidence of liver, ovarian, cervical, uterine, breast, prostate, or gallbladder malignancies.
[0050] In some embodiments, the comorbidity of diabetes (eg, type 1) is selected from diabetic nephropathy, chronic kidney disease, diabetic retinopathy, and peripheral and autonomic neuropathy.
[0051] In some embodiments, the disease or disorder is selected from diabetes (type 1 or type 2), obesity, and non-alcoholic fatty liver disease (eg, non-alcoholic steatohepatitis).
[0052] In another aspect, there is provided a process for preparing Form C of a compound of formula I as defined herein, comprising:
[0053] A first crystalline form of Formula I is suspended in water, wherein the first crystalline form exhibits an X-ray powder diffraction (XRPD) pattern having peaks at 5.89 and 17.39 in degrees 2θ (±0.2°).
[0054] 2θ) characteristic peaks;
[0055] subjecting the suspension to a temperature cycle between a first temperature and a second temperature lower than the first temperature; and
[0056] The compound of Formula I was recovered as a second crystalline form exhibiting an XRPD pattern having peaks at 6.46, 15.88, 19.44 and 5.86 degrees 2θ (±0.2° 2θ).
[0057] Represents the characteristic peaks.
[0058] In some embodiments, the first temperature is between 45°C and 65°C.
[0059] In some embodiments, the first temperature is between 50°C and 60°C.
[0060] In some embodiments, the second temperature is between 5°C and 35°C.
[0061] In some embodiments, the second temperature is between 5°C and 25°C.
[0062] In some embodiments, the first temperature is about 60°C and the second temperature is about 25°C.
[0063] In some embodiments, the method further comprises, between the temperature cycling and recovering the second crystalline form: stirring and maintaining the suspension at the second temperature.
[0064] In some embodiments, stirring and maintaining the suspension at the second temperature is performed for about 1 hour to about 12 hours.
[0065] In some embodiments, stirring and maintaining the suspension at the second temperature is performed for about 3 hours to about 6 hours.
[0066] In some embodiments, recovering the compound of Formula I as a second crystalline form comprises filtering the suspension.
[0067] In another aspect, there is provided a method of preparing Form C of a compound of Formula I as described herein, comprising:
[0068] Dissolve the compound of formula I in a solvent selected from methanol, ethanol, n-propanol and isopropanol
[0069] to obtain a solution;
[0070] adding water to the solution until solids precipitate; and
[0071] The compound of formula I is recovered as a crystalline form exhibiting an XRPD
[0072] The pattern has characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 6.46, 15.88, 19.44 and 5.86.
[0073] In some embodiments, the solvent is selected from methanol, ethanol, and n-propanol.
[0074] In some embodiments, the solvent is ethanol.
[0075] In some embodiments, dissolving the compound of Formula I in a solvent comprises dissolving the compound of Formula I as a crystalline form exhibiting an X-ray powder diffraction (XRPD) pattern having characteristic peaks expressed in degrees 2θ (±0.2° 2θ) at 5.89 and 17.39.
[0076] In some embodiments, dissolving the compound of Formula I in a solvent is performed at a first temperature between about 30°C and the boiling point of the solvent.
[0077] In some embodiments, the first temperature is from about 35°C to about 60°C.
[0078] In some embodiments, adding water is performed at the first temperature.
[0079] In some embodiments, the method further comprises cooling the solvent / water mixture to a second temperature that is lower than the first temperature.
[0080] In some embodiments, the second temperature is from about 5°C to about 30°C.
[0081] In some embodiments, the second temperature is from about 20°C to about 30°C.
[0082] In some embodiments, the solvent:water ratio (by volume) is from about 1:1 to about 3:1.
[0083] In some embodiments, the solvent:water ratio is from about 2:1 to about 3:1.
[0084] In some embodiments, recovering the compound of Formula I comprises filtering and drying the compound of Formula I.
[0085] In another aspect, there is provided a process for preparing Form C of a compound of formula I as defined herein, comprising:
[0086] providing a slurry of a first crystalline form of Formula I in a solvent selected from water, n-butanol, and a MIBK / n-heptane mixture, the first crystalline form exhibiting an X-ray powder diffraction (XRPD) pattern having characteristic peaks expressed in degrees 2θ (±0.2° 2θ) at 5.89 and 17.39;
[0087] stirring the slurry; and
[0088] The compound of formula I is recovered as a crystalline form exhibiting an XRPD
[0089] The pattern has characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 6.46, 15.88, 19.44 and 5.86.
[0090] In some embodiments, the solvent is water.
[0091] In some embodiments, the solvent is a 1:4 (v / v) MIBK:n-heptane mixture.
[0092] In some embodiments, agitating the slurry is performed at a temperature of about 50°C to about 70°C.
[0093] In some embodiments, the temperature is from about 55°C to about 65°C.
[0094] In some embodiments, the method further comprises adding seed crystals of the compound of Formula I Form C to the mixture. BRIEF DESCRIPTION OF THE DRAWINGS
[0095] Figure 1Ais a phase diagram of the anhydrate crystalline form of the compound of Formula I;
[0096] Figure 1B is an interconversion diagram of solvate and hydrate crystalline forms of the compound of formula I;
[0097] Figure 2A is the XRPD of the compound of Formula I, Form A;
[0098] Figure 2B is a graph including TGA and DSC thermograms of Form A;
[0099] Figure 2C is an XRPD overlay of Form A and Form J;
[0100] Figure 3A is an XRPD overlay of Form A with Form I and Form B obtained by temperature cycling in IPA;
[0101] Figure 3B is a graph including TGA and DSC thermograms of Form B;
[0102] Figure 4A is an XRPD overlay of Form A and Form C obtained by temperature cycling in H2O;
[0103] Figure 4B is a graph including TGA and DSC thermograms of Form C;
[0104] Figure 5A is an XRPD overlay of Form A with Form D and Form H obtained by temperature cycling in toluene;
[0105] Figure 5B is a graph including TGA and DSC thermograms of Form D;
[0106] Fig. 6A is an XRPD overlay of Form A with Form E and Form P obtained by temperature cycling in IPAc / MTBE (1:3 v / v);
[0107] Figure 6B are graphs including TGA and DSC thermograms of Form E;
[0108] Figure 6C is a graph comprising a cyclic DSC thermogram of Form E;
[0109] Fig. 7A is an XRPD overlay of Form A with Form G and Form F obtained by room temperature slurry in THF / H2O (0.92 / 0.08 v / v Aw=0.2 and 0.83 / 0.17 v / v Aw=0.4, respectively);
[0110] Figure 7B is a graph including TGA and DSC thermograms of Form F;
[0111] Fig. 8A is an XRPD overlay of Form A and Form K obtained by crash cooling in anisole;
[0112] Figure 8B is a graph including TGA and DSC thermograms of Form K;
[0113] Figure 8C is an XRPD overlay of Form K and Form K heated to 90° C. and cooled back to room temperature;
[0114] Fig.9A is an XRPD overlay of Form A and Form L obtained by rapid cooling in anisole;
[0115] Fig. 9B is a graph including TGA and DSC thermograms of Form L;
[0116] Fig. 10A is an XRPD overlay of Form A and Form M obtained by rapid cooling in IPAc;
[0117] Fig. 10B is a graph including TGA and DSC thermograms of Form M;
[0118] Fig.11A is an XRPD overlay of Form A and Form N obtained by temperature cycling in CHCl3 / n-heptane (1:3 v / v);
[0119] Fig. 11B are graphs including TGA and DSC thermograms of Form N;
[0120] Fig. 12A is an XRPD overlay of Form A and Form O obtained by slow evaporation in MeOH;
[0121] Fig. 12B are graphs including TGA and DSC thermograms of Form O;
[0122] Fig.13A is an XRPD overlay of Form A and Form Q obtained by slow evaporation of Form A slurried in n-butanol at 100°C;
[0123] Fig. 13B are graphs including TGA and DSC thermograms of Form Q;
[0124] Fig.14 is an XRPD overlay of a 5 gram scale-up batch showing that Form C was obtained; and
[0125] Fig.15 is an overlay of the simulated and experimental XRPD patterns of Form B from single crystal X-ray diffraction data. DETAILED DESCRIPTION
[0126] definition
[0127] As used herein, the term "stable" includes chemical stability and / or solid state stability. A compound is considered to be chemically stable if it can be stored in an isolated solid form, or in a solid formulation (wherein the compound can be provided in admixture with a pharmaceutically acceptable carrier, diluent or adjuvant) under normal storage conditions without any significant degree of chemical degradation or decomposition.
[0128] A compound is considered to have solid-state stability if it can be stored under normal storage conditions in an isolated solid form, or in a solid formulation (in which the compound may be provided in admixture with a pharmaceutically acceptable carrier, diluent or adjuvant), without undergoing any significant degree of solid-state transformation (e.g., crystallization, recrystallization, loss of crystallinity, solid-state phase change, hydration, dehydration, deliquesce, solvation or desolvation).
[0129] The crystalline form of a solid chemical compound not only affects its dissolution behavior (i.e., bioavailability), but also affects its solid-state stability. A way to compare the solid-state stability of a crystalline form is to evaluate the relative "thermodynamic stability" of the crystalline form. In order to evaluate the thermodynamic stability of a crystalline form, typical techniques include but are not limited to slurrying, slow evaporation, slow cooling, slow anti-solvent addition, or a combination of these methods. Calorimetric techniques (e.g., differential scanning calorimetry) can also be used to measure thermal events and phase transitions over a wide temperature range, and the comparison between the crystalline forms can provide an indication of their relative thermodynamic stability.
[0130] As used herein, the expression "pharmaceutically acceptable carrier or excipient" includes, but is not limited to, any adjuvant, carrier, glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier known to be acceptable for human or veterinary pharmaceutical use.
[0131] As used herein, the expression "pharmaceutical composition" refers to a preparation of a compound and a pharmaceutically acceptable carrier or excipient.
[0132] As used herein, the term "about" generally means within an acceptable standard error range of the mean when considered by those skilled in the art. For example, depending on the value or range under consideration, the term "about" can mean within 10%, within 5%, or within 1% of the value or range.
[0133] As used herein, the term "hydrate" refers to a crystalline form of a molecule that further comprises water molecules incorporated into the lattice structure. The water molecules in the hydrate may exist in a regular arrangement and / or a disordered arrangement. The hydrate may contain stoichiometric or non-stoichiometric amounts of water molecules. For example, a hydrate with a non-stoichiometric amount of water molecules may be due to a partial loss of water in the hydrate.
[0134] As used herein, the term "anhydrate" or "anhydrous" refers to the crystalline form of the molecule itself, which does not further comprise water molecules incorporated into the crystal lattice structure.
[0135] As used herein, the term "solvate" refers to a crystalline form of a molecule, which further comprises molecules of one or more solvents incorporated into the lattice structure. The solvent molecules in the solvate can exist in a regular arrangement and / or disordered arrangement. The solvate can contain stoichiometric or non-stoichiometric amounts of solvent molecules. For example, a solvate with a non-stoichiometric amount of solvent molecules may be due to a partial loss of the solvent in the solvate. The solvent may include various organic solvents. It should also be understood that a "solvate" may include a single solvent, a mixture of solvents, or a mixture of a solvent (or multiple solvents) and water.
[0136] The term "substantially identical" as used herein to describe an X-ray diffraction pattern is intended to include patterns with peaks within a standard deviation of ±0.2° 2θ, or X-ray diffraction patterns containing at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 peaks in common with a reference pattern. In addition, those skilled in the art will appreciate that relative peak intensities will show instrumental variability as well as variability due to crystallinity, preferred orientation, prepared sample surface, and other factors. Therefore, relative peak intensities should be considered a qualitative measure.
[0137] This specification provides a crystalline form of a compound of formula I:
[0138]
[0139] The structures depicted for compounds of Formula I are also intended to include all tautomeric forms of compounds of Formula I. In addition, the structures depicted herein are also intended to include compounds that differ only in the presence or absence of one or more isotopically enriched atoms. For example, in addition to the replacement of a hydrogen by a deuterium or tritium or a carbon by a 13 C- or 14 Compounds having structures other than C-enriched carbon substitutions of the compounds of Formula I are also within the scope of the present description.
[0140] When used in connection with a crystalline form of a compound of formula I, the term "substantially pure" is intended to include a crystalline form having a purity greater than about 90%. This means that the crystalline form may not contain more than about 10% of any other compound, and in particular, does not contain more than about 10% of any other crystalline form of the compound of formula I. Preferably, the term "substantially pure" refers to a crystalline form having a purity greater than about 95%. This means that the crystalline form may not contain more than about 5% of any other compound, and in particular, does not contain more than about 5% of any other crystalline form of the compound of formula I. More preferably, the term "substantially pure" refers to a crystalline form having a purity greater than about 99%. This means that the crystalline form may not contain more than about 1% of any other compound, and in particular, does not contain more than about 1% of any other crystalline form of the compound of formula I.
[0141] When used in connection with a compound of Formula I, the term "solid" or "solid mixture" refers to a mixture of crystalline forms. For example, a solid or solid mixture may include at least two different crystalline forms of a compound of Formula I. For example, a solid mixture may include crystalline Form C and one or more additional crystalline forms, such as Form A, Form B, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, Form N, Form O, Form P, and / or Form Q.
[0142] XRPD data were obtained using Panalytical TM The X-ray powder diffractometer was used. The radiation used was Cu Kα It is understood that the 2θ values listed herein are dependent upon the form of radiation used, and one skilled in the art will appreciate that an XRPD of a given crystalline form will exhibit different 2θ values if different radiation (eg, platinum radiation) is used.
[0143] As used herein, the term "optically pure" refers to a compound comprising a desired enantiomer in a greater proportion than the other enantiomers. An optically pure compound is typically composed of at least about 90%, 95% or 99% of the desired enantiomer based on 100 wt% total weight of the compound.
[0144] As used herein, the term "crystalline form" or "polymorph" refers to a crystal structure of a compound that has the same chemical composition but differs in the spatial arrangement of the molecules, atoms and / or ions that make up the crystal structure.
[0145] Seventeen crystalline forms were obtained by polymorph screening of the compound of Formula I, including Forms A to Q. Some crystalline forms can be converted to other crystalline forms, as will be described in detail herein.
[0146] Form A
[0147] Crystalline Form A is an anhydrate. According to DSC, Form A has an endotherm starting at about 152.2° C. and having a peak temperature of about 162.3° C. TGA analysis of Form A shows a weight loss of about 0.01% up to 200° C.
[0148] The XRPD pattern of Form A is Figure 2A The XRPD pattern exhibited by Form A has characteristic peaks represented by degrees 2θ (± 0.2° 2θ) at 5.89 and 17.39. The XRPD pattern of Form A can also be displayed at 9.39 and 17.80 with other characteristic peaks represented by degrees 2θ (± 0.2° 2θ). The XRPD pattern of Form A can also be displayed at 12.96 with another characteristic peak represented by degrees 2θ (± 0.2° 2θ). The XRPD pattern of Form A can also be displayed at 19.85 with another characteristic peak represented by degrees 2θ (± 0.2° 2θ). The XRPD pattern of Form A can also be displayed at 16.96 with another characteristic peak represented by degrees 2θ (± 0.2° 2θ).
[0149] Form A can be prepared by adding water as an anti-solvent to a solution of the compound of Formula I in acetonitrile. Form A can also be prepared by adding water as an anti-solvent to a solution of the compound of Formula I in acetone. Form A can also be prepared by adding heptane as an anti-solvent to a solution of the compound of Formula I in acetone. Form A can be prepared by adding MTBE as an anti-solvent to a solution of the compound of Formula I in acetonitrile.
[0150] Form A can be prepared by dissolving the compound of formula I in a solvent and evaporating the solvent until a crystalline material is formed (e.g., slow evaporation crystallization). The solvent can be, for example, selected from DCM, CHCl3, MEK and acetonitrile.
[0151] Form A can also be prepared by slowly cooling a solution of a compound of Formula I in a solvent or solvent mixture selected from IPA, toluene, MTBE, EtOH / n-heptane and CHCl3 / MTBE. For example, the solvent mixture can have the following ratios (v:v): EtOH / n-heptane (1:4) and CHCl3 / MTBE (1:4).
[0152] Form A can also be prepared by triturating a compound of Formula I in DCM / n-heptane (eg, 1 / 1 v / v). The trituration can be carried out, for example, at a temperature of about 25°C to about 35°C.
[0153] Form B
[0154] Crystalline Form B is an IPA solvate. According to DSC, Form B has an endotherm starting at about 126.4° C. and having a peak temperature of about 136.3° C. TGA analysis of Form B shows a weight loss of about 5.34% up to 174.0° C.
[0155] The XRPD pattern of Form B is Figure 3A (Form B) is substantially the same. The XRPD pattern exhibited by Form B has characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ) at 6.60, 6.83 and 15.02. The XRPD pattern of Form B can also be displayed at 9.09 and 9.73 with other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form B can also be displayed at 15.40 and 9.88 with other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form B can also be displayed at 21.90, 19.84 and 14.32 with other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form B can also be displayed at 26.56, 15.82 and 23.39 with other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ).
[0156] Form C
[0157] Crystalline Form C is an anhydrate. According to DSC, Form C has an endotherm starting at about 157.1° C. and having a peak temperature of about 167.9° C. TGA analysis of Form C shows a weight loss of about 0.32% up to 175.0° C.
[0158] The XRPD pattern of Form C is Figure 4A (Form C) is substantially the same. The XRPD pattern exhibited by Form C has characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ) at 6.46, 15.88, 19.44 and 5.86. The XRPD pattern of Form C can also be displayed at 7.46, 22.15 and 26.24. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form C can also be displayed at 3.81, 17.17 and 20.84. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form C can also be displayed at 17.95, 15.43 and 24.24. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form C can also be displayed at 21.53, 25.11 and 23.34. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form C may also show other characteristic peaks expressed in degrees 2θ (± 0.2° 2θ) at 14.94, 27.38 and 28.41. The XRPD pattern of Form C may also show other characteristic peaks expressed in degrees 2θ (± 0.2° 2θ) at 30.57, 12.94 and 14.50.
[0159] Form C can be prepared as follows: suspending Form A of the compound of Formula I in water; subjecting the suspension to a temperature cycle between a first temperature and a second temperature lower than the first temperature; and recovering Form C. In some embodiments, the first temperature is 45°C to 65°C, or about 50°C to about 60°C. In some embodiments, the second temperature is about 5°C to about 35°C, or about 5°C to about 25°C. In some embodiments, the first temperature is about 60°C and the second temperature is about 25°C. In some embodiments, preparing Form C further comprises stirring and maintaining the suspension at a second temperature between temperature cycling and recovering Form C. In some embodiments, stirring and maintaining the suspension at a second temperature for about 1 hour to about 12 hours, or about 3 hours to about 6 hours, or about 4.5 hours. In some embodiments, preparing Form C further comprises recovering the compound of Formula I as a second crystalline form, comprising filtering the suspension.
[0160] Form C can also be prepared as follows: dissolving the compound of formula I in a solvent selected from methanol, ethanol, n-propanol and isopropanol to obtain a solution; adding water to the solution until a solid precipitates; and recovering the precipitated solid as form C. In some embodiments, the solvent is selected from methanol, ethanol and n-propanol. In some embodiments, the solvent is ethanol. In some embodiments, wherein dissolving the compound of formula I in the solvent includes dissolving the compound of formula I as form A. In some embodiments, dissolving the compound of formula I in the solvent is carried out at a first temperature between about 30°C and the boiling point of the solvent. In some embodiments, the first temperature is about 35°C to about 60°C. In some embodiments, adding water is carried out at the first temperature. In some embodiments, preparing form C further includes cooling the solvent / water mixture to a second temperature lower than the first temperature. In some embodiments, the second temperature is about 5°C to about 30°C, or about 20°C to about 30°C. In some embodiments, the ratio of solvent: water (v / v) is about 1:1 to about 3:1, or about 2:1 to about 3:1. In some embodiments, recovering the compound of Formula I Form C comprises filtration and drying.
[0161] Form C can also be prepared by providing a slurry of the compound of Formula I Form A in a solvent selected from water and a MIBK / n-heptane mixture; stirring the slurry; and recovering the compound of Formula I as Form C. In some embodiments, the solvent is water. In other embodiments, the solvent is a 1:4 (v / v) MIBK:n-heptane mixture. In some embodiments, the stirring of the slurry is carried out at a temperature of about 50°C to about 70°C or about 55°C to about 65°C.
[0162] like Figure 1AAs shown, Form C can also be prepared by slurrying any of the anhydrate crystalline forms A, D, E, N and Q in n-butanol at 25°C or 50°C to convert the corresponding anhydrate crystalline form to Form C.
[0163] In some embodiments, seeds of Form C can be added to any of the methods for preparing Form C described herein.
[0164] Form D
[0165] Crystalline Form D is an anhydrate. According to DSC, Form D has an endotherm starting at about 155.9° C. and having a peak temperature of about 163.9° C. TGA analysis of Form D shows a weight loss of about 0.07% up to 180.0° C.
[0166] The XRPD pattern of Form D is Figure 5A (Form D) is substantially the same. The XRPD pattern exhibited by Form D has characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ) at 5.94, 11.27 and 11.86. The XRPD pattern of Form D can also be displayed at 20.75, 8.82 and 24.74. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form D can also be displayed at 4.43, 22.79 and 19.66. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form D can also be displayed at 19.41, 12.34 and 26.91. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form D can also be displayed at 12.08 and 20.98. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form D may also show additional characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 18.53 and 16.89.
[0167] Form E
[0168] Crystalline Form E is an anhydrate. According to DSC, Form E has two endotherms, starting at 120.6°C and 146.0°C, respectively, and peak temperatures at 129.5°C and 154.6°C, respectively. TGA analysis of Form E shows a weight loss of approximately 0.317% up to 177.9°C.
[0169] The XRPD pattern of Form E is Fig. 6A(Form E) is substantially the same. The XRPD pattern exhibited by Form E has characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ) at 6.62, 8.95 and 8.01. The XRPD pattern of Form E can also be displayed at 17.94, 22.30 and 24.31. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form E can also be displayed at 16.29, 12.82 and 18.83. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form E can also be displayed at 23.45, 26.11 and 20.62. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form E can also be displayed at 15.95 and 13.86. The XRPD pattern of Form E may also show additional characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 25.65 and 10.22.
[0170] Form F
[0171] Crystalline Form F is a THF solvate. According to DSC, Form F has a broad endotherm starting at about 119.5° C. and having a peak temperature of about 132.4° C. TGA analysis of Form F shows a weight loss of about 1.85% up to 165.0° C.
[0172] The XRPD pattern of Form F is Fig. 7A (Form F) is substantially the same. The XRPD pattern exhibited by Form F has characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ) at 7.51, 22.37 and 7.89. The XRPD pattern of Form F can also be displayed at 18.95, 20.25, 17.62 and 11.22. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form F can also be displayed at 11.73, 23.13, 9.26 and 5.66. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form F can also be displayed at 12.53, 9.64, 15.69 and 4.17. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form F may also show other characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 19.91, 14.32, 12.22, and 13.51.
[0173] Form G
[0174] Crystalline Form G is an unstable solvate which converts to Form F upon drying.
[0175] The XRPD pattern of Form G is Fig. 7A(Form G) is substantially the same. The XRPD pattern exhibited by Form G has characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ) at 18.86, 25.22 and 6.28. The XRPD pattern of Form G can also be displayed at 38.23, 31.67 and 21.95. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form G can also be displayed at 10.88 and 8.36. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form G can also be displayed at 19.75 and 12.56. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form G can also be displayed at 20.51 and 22.74.
[0176] Form H
[0177] Crystalline Form H is an unstable solvate which converts to Form D upon drying.
[0178] The XRPD pattern of Form H is Figure 5A (Form H) is substantially the same. The XRPD pattern exhibited by Form H has characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ) at 5.73, 10.90 and 11.45. The XRPD pattern of Form H can also be displayed at 19.12, 16.68 and 18.86. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form H can also be displayed at 20.35, 23.96, 26.36 and 22.03. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form H can also be displayed at 24.18, 12.02, 22.62 and 15.90. The XRPD pattern of Form H may also show other characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 16.43, 6.01, 8.73, 20.84, and 4.36.
[0179] Form I
[0180] Crystalline Form I is an unstable solvate which converts to Form B upon drying.
[0181] The XRPD pattern of Form I is Figure 3A(Form I) is substantially the same. The XRPD pattern exhibited by Form I has characteristic peaks represented by degrees 2θ (± 0.2° 2θ) at 6.28, 8.43 and 18.77. The XRPD pattern of Form I can also be displayed at 17.18, 7.78 and 21.51. Other characteristic peaks represented by degrees 2θ (± 0.2° 2θ). The XRPD pattern of Form I can also be displayed at 11.77, 19.40 and 17.96. Other characteristic peaks represented by degrees 2θ (± 0.2° 2θ). The XRPD pattern of Form I can also be displayed at 10.39, 25.55 and 15.56. Other characteristic peaks represented by degrees 2θ (± 0.2° 2θ). The XRPD pattern of Form I can also be displayed at 9.00, 14.23, 23.00 and 15.25. Other characteristic peaks represented by degrees 2θ (± 0.2° 2θ). The XRPD pattern of Form I may also show other characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 20.84, 16.47, 21.02, and 26.47.
[0182] Form J
[0183] Crystalline Form J is an unstable solvate which converts to Form J upon drying.
[0184] The XRPD pattern of Form J is Figure 2C (Form J) is substantially the same. The XRPD pattern exhibited by Form J has characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ) at 5.59 and 16.76. The XRPD pattern of Form J can also be displayed at 9.35 and 22.43 with other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form J can also be displayed at 22.75, 21.63 and 26.63 with other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form J can also be displayed at 18.78, 21.11 and 24.05 with other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form J can also be displayed at 18.10, 24.62 and 16.17 with other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ).
[0185] Form K
[0186] Crystalline Form K is a hemihydrate. According to DSC, Form K exhibits two endothermic events, starting at 53.6°C and 106.3°C, respectively, and peak temperatures at 68.7°C and 125.9°C, respectively. TGA analysis of Form K shows a weight loss of approximately 1.35% up to 160.0°C.
[0187] The XRPD pattern of Form K is Fig. 8A(Form K) is substantially the same. The XRPD pattern exhibited by Form K has characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ) at 6.65 and 6.92. The XRPD pattern of Form K can also be displayed at 26.74 and 20.02. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form K can also be displayed at 15.55 and 27.75. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form K can also be displayed at 15.13, 9.94 and 17.89. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form K can also be displayed at 13.79, 30.57 and 9.13. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ).
[0188] Form L
[0189] Crystalline Form L is a partially desolvated anisole solvate with a stoichiometry of API: anisole of approximately 0:0.26. According to DSC, Form L exhibits a single endothermic event in the DSC curve that occurs after solvent drive, starting at 126.4° C. and having a peak temperature of 133.8° C. TGA analysis of Form L shows that the weight loss until 165° C. is approximately 4.56%.
[0190] The XRPD pattern of Form L is Fig.9A (Form L) is substantially the same. The XRPD pattern exhibited by Form L has characteristic peaks represented by degrees 2θ (± 0.2°2θ) at 6.07 and 6.65. The XRPD pattern of Form L can also be displayed at 5.24 with another characteristic peak represented by degrees 2θ (± 0.2°2θ). The XRPD pattern of Form L can also be displayed at 20.64 with another characteristic peak represented by degrees 2θ (± 0.2°2θ). The XRPD pattern of Form L can also be displayed at 8.03 with another characteristic peak represented by degrees 2θ (± 0.2°2θ). The XRPD pattern of Form L can also be displayed at 22.38 with another characteristic peak represented by degrees 2θ (± 0.2°2θ). The XRPD pattern of Form L can also be displayed at 17.99 with another characteristic peak represented by degrees 2θ (± 0.2°2θ).
[0191] Form M
[0192] Crystalline Form M is an IPAc monosolvate. According to DSC, Form M shows 2 overlapping endothermic events, which start at 109°C and have peak temperatures of 116.7°C and 128.2°C, which occur simultaneously with the TGA weight loss step. TGA analysis of Form M shows a weight loss of 13.33% until 165.0°C.
[0193] The XRPD pattern of Form M is Fig. 10A (Form M) is substantially the same. The XRPD pattern exhibited by Form M has characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ) at 6.59, 8.26 and 19.79. The XRPD pattern of Form M can also be displayed at 22.71 and 26.49. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form M can also be displayed at 17.84 and 14.38. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form M can also be displayed at 4.73, 24.57 and 12.25. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form M can also be displayed at 20.69, 13.29 and 16.40.
[0194] Form N
[0195] Crystalline Form N is an anhydrate. According to DSC, Form N exhibits a single endotherm with an onset at 141.9° C. and a peak temperature of 152.1° C. TGA analysis of Form N shows a weight loss of 0.46% up to 179.0° C.
[0196] The XRPD pattern of Form N is Fig.11A (Form N) is substantially the same. The XRPD pattern exhibited by Form N has characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ) at 6.12, 4.16 and 19.29. The XRPD pattern of Form N can also be displayed at 3.32 and 16.65. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form N can also be displayed at 4.63 and 3.11. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form N can also be displayed at 21.81, 22.45 and 26.20. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form N can also be displayed at 9.93, 9.12 and 18.05.
[0197] Form O
[0198] Crystalline Form O is a methanol monosolvate. According to DSC, Form O exhibits a broad endotherm with an onset at 107.4° C. and a peak temperature at 110.6° C. TGA analysis of Form O shows a weight loss of 5.11% up to 160.0° C.
[0199] The XRPD pattern of Form O is Fig. 12A(Form O) is substantially the same. The XRPD pattern exhibited by Form O has characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ) at 5.59 and 16.76. The XRPD pattern of Form O can also be displayed at 28.10 and 6.63. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form O can also be displayed at 11.16 and 22.41. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form O can also be displayed at 33.87 and 25.38. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form O can also be displayed at 11.89 and 16.20. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ).
[0200] Form P
[0201] Crystalline Form P is an unstable solvate which converts to Form E upon drying.
[0202] The XRPD pattern of Form P is Fig. 6A (Form P) is substantially the same. The XRPD pattern exhibited by Form P has characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ) at 5.38, 16.69 and 6.93. The XRPD pattern of Form P can also be displayed at 11.61, 21.89 and 8.95. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form P can also be displayed at 19.84 and 17.85. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form P can also be displayed at 20.82 and 15.86. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form P can also be displayed at 12.35 and 22.99.
[0203] Form Q
[0204] Crystalline Form Q is an anhydrate. According to DSC, Form Q exhibits a single broad endotherm with an onset at 101.4° C. and a peak temperature of 130.1° C. TGA analysis of Form Q shows a weight loss of 0.63% up to 160.0° C.
[0205] The XRPD pattern of Form Q is Fig.13A(Form Q) is substantially the same. The XRPD pattern exhibited by Form Q has characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ) at 13.58, 5.61 and 16.82. The XRPD pattern of Form Q can also be displayed at 12.34, 21.73 and 19.39. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form Q can also be displayed at 14.95, 20.94 and 18.73. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form Q can also be displayed at 12.78, 23.31, 26.25 and 28.21. Other characteristic peaks represented by degrees 2θ (± 0.2 ° 2θ). The XRPD pattern of Form Q may also show other characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 17.69, 8.37, 24.47, and 31.84.
[0206] Preparations, methods and uses
[0207] As used herein, the term "effective amount" refers to the amount of a drug or pharmaceutical agent that will elicit a biological or medical response in a tissue, system, animal or human being that is being sought, for example, by a researcher or clinician. In addition, the term "therapeutically effective amount" refers to any amount that results in an improved treatment, cure, prevention or amelioration of a disease, condition or side effect, or a decreased rate of progression of a disease or condition, compared to a corresponding subject not receiving that amount. The term also includes within its scope amounts that are effective in enhancing normal physiological function.
[0208] As used herein, the terms "treat" and "treat" refer to reversing, alleviating a disease or condition as described herein or one or more symptoms thereof, delaying its onset, or inhibiting its progression. In some embodiments, treatment may be administered after one or more symptoms have occurred. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to susceptible individuals before the onset of symptoms (e.g., based on a history of symptoms and / or based on genetic or other predisposing factors). Treatment may also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.
[0209] As used herein, the term "patient or subject" refers to a mammal. Thus, the subject refers to, for example, a dog, a cat, a horse, a cow, a pig, a guinea pig, etc. Preferably, the subject is a human. When the subject is a human, the subject can be a patient or a healthy person.
[0210] Formula I compounds can be used to treat diseases and conditions that require inhibition of cannabinoid receptor CB1, such as those described in U.S. Patent No. 9,765,031. Such diseases and conditions are generally associated with diabetes and metabolic disorders (e.g., metabolic syndrome). Preferably, the active ingredient selectively targets CB1 receptors in peripheral tissues (e.g., adipose tissue, liver, muscle, lung, kidney, macrophage, pancreatic beta cell, and gastrointestinal tract), without interacting with CB1 receptors in brain tissue, thereby avoiding or reducing side effects associated with CNS.
[0211] The effects of the compounds of formula I may include reducing food intake, reducing body weight, reversing insulin and leptin resistance, reversing hepatic steatosis (fatty liver), and improving dyslipidemia. Examples of diseases and conditions to be treated include obesity, diabetes (type 1 or type 2), nonalcoholic and alcoholic fatty liver disease (risk factor for insulin resistance), comorbidities of obesity, comorbidities of diabetes, Prader-Willi syndrome (PWS), pro-opiomelanocortin (POMC) deficiency obesity, LepR deficiency obesity, POMC heterozygous deficiency obesity, POMC epigenetic disorders, Bardet-Biedl syndrome, Syndrome, dyslipidemia, diabetic nephropathy, fibrosis and fibrotic diseases that are prone to develop into arteriosclerotic heart disease, such as idiopathic pulmonary fibrosis (IPF) and Hermansky-Pudlak syndrome pulmonary fibrosis (HPS-PF), and gout.For example, the comorbidity of obesity is selected from metabolic syndrome, dementia, heart disease, hypertension, gallbladder disease, gastrointestinal disorders, menstrual disorders, degenerative arthritis, venous stasis ulcer, hypoventilation syndrome, sleep apnea, snoring, coronary artery disease, arteriosclerotic disease, pseudotumor cerebri, osteoarthritis, high cholesterol, and liver, ovary, cervix, uterus, breast, prostate or gallbladder malignant tumor incidence rate increases.In a preferred example, the disease or illness include diabetes (type 1 or type 2), obesity and nonalcoholic fatty liver disease (such as nonalcoholic steatohepatitis).The example of the comorbidity of diabetes (such as type 1) includes diabetic nephropathy, chronic kidney disease, diabetic retinopathy and peripheral and autonomic neuropathy.
[0212] The compounds of Formula I and pharmaceutical compositions comprising the compounds of Formula I may also be used in methods of preventing or reversing adipose tissue deposition in a subject, which is expected to help reduce the incidence or severity of obesity and, in turn, the incidence or severity of related comorbidities.
[0213] This specification provides a method for treating a disease (as described herein) of a subject, comprising administering a compound of formula I to a subject determined to be in need. The determination of patients who need to treat the above-mentioned disease is completely within the capabilities and knowledge of those skilled in the art. The medical field knows certain methods for determining patients with a risk of the above-mentioned disease that can be treated by the method of the present invention, such as family history, and the presence of risk factors associated with the occurrence of the disease state in the patient. Clinicians in the art can easily determine such candidate patients by utilizing, for example, clinical trials, physical examinations, medical history / family history, and genetic testing.
[0214] The method for evaluating the efficacy of treatment in a subject includes determining the pre-treatment symptoms of the disease by methods known in the art, and then administering a therapeutically effective amount of the compound of the present specification to the subject. After a suitable period of time (e.g., 1 week, 2 weeks, 1 month, 6 months) after the compound is administered, the symptoms of the disease are determined again. The regulation (e.g., reduction) of the symptoms of the disease and / or biomarkers indicates the efficacy of the treatment. The symptoms and / or biomarkers of the disease can be regularly determined throughout the treatment process. For example, the symptoms and / or biomarkers of the disease can be checked every few days, weeks, or months to assess the further efficacy of the treatment. The reduction of the symptoms and / or biomarkers of the disease indicates that the treatment is effective.
[0215] The compositions described herein can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
[0216] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compound, the liquid dosage form may also contain inert diluents commonly used in the art, for example, water or other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (particularly cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofuran alcohol, polyethylene glycol, and fatty acid esters of sorbitan, and mixtures thereof. In addition to inert diluents, oral compositions may also include adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents, and aromatics.
[0217] Injectable products, such as sterile injectable aqueous or oily suspensions, can be prepared according to known techniques using suitable dispersants or wetting agents and suspending agents. Sterile injectable products can also be sterile injectable solutions, suspensions or emulsions in nontoxic parenteral acceptable diluents or solvents, such as solutions in 1,3-butanediol. Acceptable vehicles and solvents that can be used include water, Ringer's solution USP and isotonic sodium chloride solution. In addition, routine use of sterile fixed oils as solvents or suspension media. For this reason, any soft fixed oil can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
[0218] The injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0219] In order to prolong the effect of the compound provided, it may be desirable to slow down the absorption of the compound from subcutaneous or intramuscular injection. This can be achieved by using a liquid suspension of a crystalline or amorphous substance with poor water solubility. The absorption rate of the compound depends on its dissolution rate, which in turn may depend on crystal size and crystalline form. Alternatively, the delayed absorption of the compound form administered parenterally is achieved by dissolving or suspending the compound in an oily vehicle. The injectable depot form is prepared by forming a microencapsulated matrix of the compound in a biodegradable polymer such as polylactide-polyglycolide. The rate of compound release can be controlled according to the ratio of the compound to the polymer and the properties of the specific polymer used.
[0220] Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
[0221] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of the present disclosure with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which is solid at ambient temperature but liquid at body temperature and therefore melts in the rectum or vaginal cavity and releases the active compound.
[0222] Solid dosage forms for oral administration include capsules, tablets, pills and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and / or the following substances: a) fillers or extenders such as starch, lactose, sucrose, glucose, mannitol and silicic acid, b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and acacia, c) humectants such as glycerol, d) disintegrators such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate, e) dissolution delay agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as cetyl alcohol and glyceryl monostearate, h) adsorbents such as kaolin and bentonite, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
[0223] Solid compositions of similar form can also be used as fillers in soft and hard filled gelatin capsules using auxiliary materials such as lactose or milk sugar and high molecular weight polyethylene glycol, etc. The solid dosage forms of tablets, lozenges, lozenges, capsules, pastilles, pills and granules can be prepared with coatings and shells, such as enteric coatings and other coatings known in the field of pharmaceutical preparation. They can optionally contain opacifiers and can also have such a composition: they only or preferentially release active ingredients in a certain part of the intestinal tract, optionally in a delayed manner. The example of the embedding composition that can be used includes polymeric substances and waxes. Solid compositions of similar form can also be used as fillers in soft and hard filled gelatin capsules using auxiliary materials such as lactose or milk sugar and high molecular weight polyethylene glycol, etc.
[0224] The compound provided can also be in a microencapsulated form containing one or more adjuvants as described above. The solid dosage forms of tablets, lozenges, troches, capsules, pastilles, pills and granules can be prepared with coatings and shells, such as enteric coatings, release control coatings and other coatings known in the field of pharmaceutical formulation. In such solid dosage forms, the active compound can be mixed with at least one inert diluent such as sucrose, lactose or starch. According to conventional practice, such dosage forms can also include additional substances other than inert diluents, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage form can also include a buffer. They can optionally include a sunscreen and can also have such a composition: they only or preferentially release the active ingredient in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
[0225] The dosage form of the compound for topical or transdermal administration of this specification includes ointment, paste, cream, lotion, gel, powder, solution, spray, inhalant or patch. Active ingredient is mixed under aseptic conditions with a pharmaceutically acceptable carrier and any required preservative or buffer that may be needed. Ophthalmic preparations, ear drops and eye drops are also considered within the scope of this specification. In addition, this specification also contemplates the use of transdermal patches, which have the additional advantage of providing controlled delivery of compounds to the body. Such dosage forms can be prepared by dissolving or being dispersed in the appropriate medium. Absorption enhancers can also be used to increase the flux of compounds through the skin. Rate control can be provided by providing a rate control membrane or by dispersing the compound in a polymer matrix or a gel to control the rate.
[0226] The pharmaceutically acceptable compositions provided herein can also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and can be prepared as solutions in saline with the use of benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.
[0227] The pharmaceutically acceptable compositions provided herein can be formulated for oral administration. Such preparations can be administered with or without food. In some embodiments, the pharmaceutically acceptable compositions of the present disclosure are not administered with food. In other embodiments, the pharmaceutically acceptable compositions of the present disclosure are administered with food.
[0228] The pharmaceutically acceptable compositions provided herein can be formulated for oral administration. Such preparations can be administered with or without food. The compositions are formulated into unit dosage forms for ease of administration and uniformity of dosage. The expression "unit dosage form" as used herein refers to physically discrete dosage units suitable for patients to be treated. However, it should be understood that the total daily dosage of the compositions disclosed herein will be determined by the attending physician within the scope of reasonable medical judgment.
[0229] The amount of the compound of formula I that can be included in a single dosage form will be different according to the patient to be treated (e.g., children and adults, etc.). The provided composition can be formulated so that a total daily dose of, for example, 0.01 to 20 mg / kg body weight / day can be applied to the patient receiving these compositions. The single-dose composition can contain such an amount, or the total daily dose can be divided into multiple dosage forms for application, for example, once, twice or three times a day. For example, a single dose can include 5 to 500 mg or 20 to 200 mg of active ingredient. The treatment regimen can include applying a total amount of about 10 mg to about 1000 mg of the present specification to the patient in a single dose or divided into multiple doses every day.
[0230] It should be understood that the total daily dose of the compound of Formula I will be determined by the attending physician within the scope of reasonable medical judgment. For example, the specific dosage or treatment regimen for any particular patient will depend on a variety of factors, including age, weight, general health, sex, diet, time of administration, excretion rate, drug combination, the judgment of the treating physician, and the severity of the symptoms associated with the disease or condition.
[0231] According to the disease to be treated or illness, additional therapeutic agents can also be present in the compositions of the present disclosure or be co-administered individually. The limiting examples of additional therapeutic agents that can be used in combination with Formula I compounds include antidiabetic agents, cholesterol-lowering agents, anti-inflammatory agents, antimicrobial agents, matrix metalloproteinase inhibitors, lipoxygenase inhibitors, cytokine antagonists, immunosuppressants, anticancer agents, antiviral agents, cytokines, growth factors, immunomodulators, prostaglandins or anti-angiogenic hyperproliferative compounds. Other treatments or interventions can also be supplemented for the treatment, such as surgery, radiotherapy (for example, gamma radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy and systemic radioisotopes), biological response modifiers (for example, interferon, interleukin, tumor necrosis factor (TNF)) and the medicament for alleviating the adverse reactions of the compounds of this invention or co-administering components.
[0232] The recitation of an embodiment of a variable herein includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof.
[0233] In some embodiments, a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt thereof, may be administered to a patient alone or in admixture with a pharmaceutically acceptable carrier.
[0234] The term "pharmaceutically acceptable carrier, adjuvant or vehicle" refers to a non-toxic carrier, adjuvant or vehicle that does not destroy the pharmacological activity of the compound formulated therewith. Pharmaceutically acceptable carriers, adjuvants and vehicles that can be used in the compositions of the present disclosure include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol and lanolin.
[0235] "Pharmaceutically acceptable derivative" refers to any non-toxic salt, ester, ester salt or other derivative of the compound of the present disclosure, which, after administration to a recipient, is capable of directly or indirectly providing the compound of the present disclosure or its inhibitory active metabolite or residue.
[0236] Experimental and Examples
[0237] Materials and instruments
[0238] At room temperature, Nikon TM Polarized light microscopy (PLM) images were captured using a DS-Fi2 upright microscope.
[0239] Using Panalytical TM XPert Powder XRPD performs powder X-ray diffraction (XRPD) on Si zero background. The XRPD parameters used are as follows:
[0240]
[0241] In TA Instruments TM Differential Scanning Calorimetry (DSC) was performed on a TA Q2000 DSC. The DSC method was as follows: N2 was used as the purge gas, and the temperature was increased from room temperature to the desired temperature at a heating rate of 10°C / min, using a crimped pan with a pinhole in the lid. The DSC parameters were as follows:
[0242]
[0243]
[0244] Thermogravimetric analysis (TGA) was performed on a TA Q500 TGA from TA Instruments. The TGA method was as follows: N2 was used as the purge gas and the temperature was increased from room temperature to the desired temperature (300°C) at a heating rate of 10°C / min. The TGA parameters were as follows:
[0245]
[0246] At Mettler Toledo TM Karl Fisher (KF) titration was performed on a volumetric KF titrator to determine the water content in the samples.
[0247] The solvent abbreviations are as follows:
[0248]
[0249] Summary of experimental results
[0250] A polymorph screen of the compound of formula I was performed to identify the most stable crystalline form.
[0251] The first crystalline form of the compound of formula I was obtained by the method described in Example 2. The crystalline form was characterized by X-ray powder diffraction (XRPD), polarized light microscopy (PLM), thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). The characterization results showed that the starting material was an anhydrous crystalline material with rod-shaped particles. DSC showed a single melting endotherm starting at 152.2°C. The crystalline form was designated as Form A.
[0252] Starting from Form A, a polymorph screen was performed under 100 different conditions using slurry conversion at room temperature (RT) and 60°C, temperature cycling, antisolvent addition, slow cooling, slow evaporation, polymer-induced crystallization, fast cooling, bulky solvent slurry, and reverse antisolvent addition. This screen resulted in 17 crystalline forms (Forms A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, and Q):
[0253] - Forms A, C, D, E, N and Q were found to be anhydrates;
[0254] - Forms A, D and E were found to be desolvation products of unstable solvate forms J, H and P, respectively;
[0255] - Forms C, N and Q were found to be truly anhydrous, with
[0256] No changes in the XRPD patterns were observed between the dry cake samples;
[0257] - Form K was found to be a hemihydrate (API:H2O ratio of 1:0.5);
[0258] - Forms B, F, L, M and O were found to be solvates; and
[0259] - Wet cake XRPD analysis of the solvate yielded 2 new crystalline forms, Forms I and G, which upon ambient drying yielded Forms B and F, respectively.
[0260] The six anhydrates (Forms A, C, D, E, N, Q) were thermodynamically evaluated in the nonsolvating solvent n-butanol to determine the most stable phase at room temperature and 50° C. Both experiments showed complete conversion to Form C, indicating that Form C is the most thermodynamically stable anhydrous form under these conditions.
[0261] Example 1: Polymorph Screening
[0262] Polymorph screening experiments were performed using different solution crystallization or solid phase transformation methods starting from Form A. The methods used and the crystal forms identified are summarized in Table 1-1.
[0263] Table 1-1: Summary of polymorph screening experiments
[0264]
[0265] Antisolvent addition
[0266] About 20-50 mg of Form A was dissolved in an appropriate solvent to obtain a clear solution. The solution was magnetically stirred, and then 0.2 mL of antisolvent was gradually added until a precipitate appeared or the total amount of the antisolvent reached 15.0 mL. The precipitate obtained was separated for XRPD analysis. A total of 20 experiments were performed. The results in Table 1-2 show that Forms A, C, E, G, J, N and P were obtained.
[0267] Table 1-2: Summary of antisolvent addition experiments
[0268]
[0269]
[0270] Slow evaporation
[0271] Slow evaporation experiments were performed under 10 conditions. About 20 mg of Form A was dissolved in 1.0 mL of solvent in a 3-mL glass vial. The clear solution was allowed to evaporate slowly at room temperature. The solid was isolated for XRPD analysis. The results summarized in Tables 1-3 show that Forms A, E, F, G, J and K were obtained.
[0272] Table 1-3: Summary of slow evaporation experiments
[0273]
[0274]
[0275] Rapid cooling
[0276] About 25-50 mg of Form A was dissolved in 0.2-0.6 mL of solvent to obtain a suspension. The suspension was then heated to 60 ° C using magnetic stirring, balanced for two hours, and filtered using a PTFE membrane (pore size of 0.20 μm). The filtrate was immediately transferred to a 5 ° C environment. A total of 4 experiments were performed. The results in Tables 1-4 show that Forms E, K, L, M and P were obtained.
[0277] Table 1-4: Summary of rapid cooling experiments
[0278]
[0279] Slurrying at room temperature
[0280] Slurry conversion experiments were performed in 20 solvent systems at room temperature. Approximately 15-20 mg of Form A was suspended in 0.5 mL-1.0 mL of solvent at room temperature. The remaining solid was separated for XRPD analysis. The results summarized in Tables 1-5 show that Forms A, B, E, F, G, I, N, and P were obtained.
[0281] Table 1-5: Summary of slurry conversion experiments at room temperature
[0282]
[0283]
[0284] Slurry at 60°C
[0285] Slurry conversion experiments were performed at 60°C in 10 solvent systems. Approximately 25-75 mg of Form A was suspended in 0.5 mL of solvent at 60°C for 3 days. The remaining solid was isolated for XRPD analysis. The results summarized in Tables 1-6 show that Forms B, C, D, H, I, K, and N were obtained from all experiments.
[0286] Table 1-6: Summary of slurry conversion experiments at 60°C
[0287]
[0288]
[0289] Slurrying in large volumes of solvent
[0290] Slurry conversion experiments were performed in 6 different bulk solvent systems at 60°C and 100°C. Approximately 25-75 mg of Form A was suspended in 0.5 mL of bulk solvent at the corresponding temperature and magnetically stirred. The remaining solid was separated for XRPD analysis. The results summarized in Tables 1-7 show that Forms N and Q were obtained from all experiments.
[0291] Table 1-7: Summary of slurry conversion experiments in large volumes of solvent
[0292]
[0293] Slow cooling
[0294] About 25-50 mg of Form A was dissolved in 0.2-0.6 mL of solvent to obtain a suspension. The suspension was then heated to 50 ° C using magnetic stirring, balanced for two hours, and filtered using a PTFE membrane (pore size of 0.20 μm). The filtrate was slowly cooled to 5 ° C at a rate of 0.1 ° C / min. A total of 5 experiments were performed. The results in Table 1-8 show that Forms D, H, K and L were obtained.
[0295] Table 1-8: Summary of slow cooling experiments
[0296]
[0297] Polymer-induced crystallization
[0298] Polymer induced crystallization experiments were performed using two different polymers in five solvents. About 20 mg of Form A was dissolved in 0.5-2.0 mL of an appropriate solvent in a 3-mL vial to obtain a clear solution. About 2 mg of the polymer mixture was added to a 3-mL glass vial. All samples were evaporated at room temperature to induce precipitation. The solid was separated for XRPD analysis. The results summarized in Tables 1-9 show that Forms A, J, and K were obtained.
[0299] Table 1-9: Summary of polymer-induced crystallization experiments
[0300]
[0301] Temperature Cycle
[0302] A suspension of approximately 50-100 mg / ml of Form A in 0.5 ml of solvent was magnetically stirred and cyclically exposed to high temperature (50° C.) and low temperature (5° C.). Solids were isolated on days 1 and 3 and analyzed by XRPD. As summarized in Tables 1-10, a total of 10 experiments were performed and Forms A, B, C, D, E, F, G, H, I, J, and N were obtained.
[0303] Table 1-10: Summary of temperature cycling experiments between 50°C and 5°C
[0304]
[0305] Reverse antisolvent addition
[0306] About 20-50 mg of Form A was dissolved in a suitable solvent to obtain a clear solution. The solution was then added dropwise to the corresponding antisolvent under magnetic stirring. The precipitate obtained was separated for XRPD analysis. A total of 10 experiments were performed. The results in Tables 1-11 show that Forms A, J and N were obtained.
[0307] Table 1-11: Summary of reverse antisolvent addition experiments
[0308]
[0309]
[0310] The XRPD of the isolatable form can be seen in the attached figure. The characterization results are summarized in Table 1. Figure 1A Phase diagrams of the six anhydrates are shown. Figure 1B Interconversion diagrams for all solvates and hydrates are shown.
[0311] Table 1: Characterization of the crystalline form of the compound of formula I.
[0312]
[0313]
[0314]
[0315] Example 2: Form A and Form J
[0316] Form A was obtained by the following synthetic steps:
[0317]
[0318] 1) 7.75 L of DMF was pumped into a 50 L enamel jacketed kettle under reduced pressure and stirring.
[0319] 2) 1.58 kg of compound 2 was added to the solution at 25-30°C at one time.
[0320] 3) 0.595 kg of compound 3 was added to the solution at 25-30°C in one portion.
[0321] 4) The reaction mixture was stirred at 20-30°C for 0.5h.
[0322] 5) 1.49 kg TEA was added to the solution at 25-30°C under nitrogen.
[0323] 6) The reaction mixture was stirred at 20-30°C for 1.0 h.
[0324] 7) The reaction was monitored by HPLC until completion.
[0325] 8) After completion, the reaction mixture was slowly added to 31 L of water and stirred at 10-15°C for 30 min.
[0326] 9) The reaction mixture was then filtered and the filter cake was washed with water (2000 mL). The washed filter cake was dissolved in DCM (4000 mL) and water (1000 mL) was added.
[0327] 10) The organic layer was washed with brine (3000 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a crude compound with a purity of 93.1% (according to HPLC).
[0328] 11) The crude compound of formula I was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 3 / 1 to 2 / 1, TLC: PE: EA = 1:1, p1: Rf = 0.5).
[0329] 12) The collected fractions were concentrated under reduced pressure to obtain a residue.
[0330] 13) The residue was triturated with DCM (5.0 L) and n-heptane (5.0 L) at 30°C for 1.0 h.
[0331] 14) The mixture was then filtered and the filter cake was dried under reduced pressure at 45°C.
[0332] 15) Crystalline Form A of the compound of Formula I (1.48 kg, yield 85%, purity 99.8%) was obtained as a white solid, confirmed by HPLC, LCMS and H / FNMR.
[0333] By XRPD( Figure 2A ) and PLM characterized Form A. It was shown that Form A was crystalline and had small rod-shaped particles with agglomeration.
[0334] Thermal analysis of Form A showed a weight loss of 0.01% up to 200°C and a single endothermic peak with an onset at 152.2°C and a peak temperature of 162.3°C, as shown in FIG. Figure 2B shown.
[0335] Form A obtained by anti-solvent addition in ACN / H2O was further studied by analyzing the wet solids by XRPD. The sample was covered with 3511 Kapton film to minimize solvent evaporation from the wet cake. A unique pattern different from Form A was observed, indicating that an unstable solvate phase was formed in this solvent system. This crystalline form was designated Form J. After ambient drying, Form J converted to Form A. Figure 2C An XRPD overlay of Form A and Form J is shown.
[0336] The approximate solubility of Form A was determined in 20 individual solvents at room temperature. Approximately 2 mg of Form A was added to 3-mL glass vials. Then the corresponding solvents were added stepwise (50 μL - 50 μL - 200 μL - 700 μL) to the vial until the visual solid dissolved or a total volume of 1 mL was reached. The approximate solubility range was calculated based on the mass of the sample, the volume of the solvent, and the observations. The results summarized in Table 2 were used to guide solvent selection in polymorph screening.
[0337] Form A has high solubility (>10 mg / mL) in most solvents including MeOH, EtOH, acetone, MIBK, MEK, EtOAc, IPAc, THF, 2-MeTHF, 1,4-dioxane, anisole, ACN, CHCl3, DMSO, and DCM. Moderate solubility (2.0 < S < 10.0) was observed in toluene. Low solubility (<3.0 mg / mL) was observed in IPA, MTBE, n-heptane, and H2O.
[0338] Table 2: Solubility of Form A of the Compound of Formula I
[0339]
[0340] Example 3: Form B and Form I
[0341] Form B was obtained by temperature cycling in IPA. The formation of Form B was also observed in an IPA slurry at room temperature and 60 °C. Form B was further characterized by analyzing the wet cake via XRPD. The samples on the XRPD sample holders were covered with 3511 Kapton film to minimize solvent evaporation of the samples. A unique pattern different from Form A and Form B was observed and designated as Form I. After ambient drying, Form I was converted to Form B, indicating that Form I is an unstable solvate. Figure 3A A comparison of the XRPD patterns of Form A, Form B, and Form I is shown. PLM shows irregularly shaped birefringent small particles. Figure 3B Thermal analysis in shows that according to TGA, the weight loss until 174.0 °C is 5.34%, and according to DSC, a broad endotherm starting at 126.4 °C and with a peak temperature of 136.3 °C is shown. KF analysis of Form B shows a water content of 0.5%. By comparing the KF and TGA results, the following conclusion was drawn: Form B is an IPA solvate, more specifically, a hemisolvate, which was determined by calculating the API:solvent stoichiometry as 1:0.6 from the TGA weight loss.
[0342] Example 4: Form C
[0343] Form C was obtained by temperature cycling from 60°C to 25°C in H2O. Form C formation was also observed in antisolvent addition and 60°C screening experiments. Figure 4A Shown is a comparison of the XRPD patterns of Form A and Form C. The PLM image of Form C shows small, birefringent particles of irregular shape. Figure 4B Thermal analysis in 200 % showed a weight loss of 0.32% up to 175.0° C. and exhibited a single endotherm with an onset at 157.1° C. and a peak temperature of 167.9° C. The minimal weight loss observed indicated the absence of an aqueous phase.
[0344] Example 5: Form D and Form H
[0345] Form D was obtained by temperature cycling in toluene. Form D formation was also observed in slurrying and slow cooling at 60°C using toluene. Form D was further characterized by analyzing the wet solid by XRPD. The sample on the XRPD sample holder was covered with 3511 Kapton film to minimize solvent evaporation of the sample. A unique pattern different from Form A and Form D was observed, indicating an unstable solvate phase, and it was designated as Form H. After ambient drying, Form H converted to Form D. Figure 5A A comparison of the XRPD patterns of Form A, Form D, and Form H is shown. The PLM image of Form D shows small, irregular needles with the presence of agglomerates. Figure 5B Thermal analysis in showed a weight loss of 0.07% up to 180.0° C. and exhibited a single endotherm with an onset at 155.9° C. and an enthalpy of 23.5 J / g and a peak temperature of 163.9° C. The minimal weight loss observed indicated the absence of an aqueous phase.
[0346] Example 6: Form E and Form P
[0347] Form E was obtained by temperature cycling in IPAc / MTBE (1:3 v / v). The formation of Form E was also observed in anti-solvent addition, rapid cooling and room temperature slurry experiments using MTBE, 2-MeTHF or toluene. Form E was further characterized by analyzing the wet solid by XRPD. The sample on the XRPD sample holder was covered with 3511 Kapton film to minimize solvent evaporation of the sample. A unique pattern different from Form A and Form E was observed, indicating an unstable solvate phase, and it was designated as Form P. After ambient drying, Form P converted to Form E. Fig. 6A Shown is a comparison of the XRPD patterns of Form A, Form E, and Form P. The PLM image of Form E shows small, birefringent particles of irregular shape. Figure 6BThermal analysis in showed a weight loss of 0.31% up to 177.9° C. and exhibited two endotherms, onset at 120.6° C. and 146.0° C., respectively, and peak temperatures at 129.5° C. and 154.6° C., respectively. The minimal weight loss observed indicated the absence of an aqueous phase.
[0348] The first small endotherm was further investigated to determine if conversion to another form occurred upon heating beyond the first small endotherm and before the final melting endotherm, followed by cooling back to room temperature. Figure 6C The cyclic DSC shown in was performed by heating to 135°C in cycle 1, cooling to room temperature in cycle 2, and then heating to 300°C (beyond the final melt) in cycle 3. In cycle 2, the endothermic event that occurred in cycle 1 (starting at 122.1°C) was observed upon cooling, indicating that this was a reversible event. In the final cycle, the first endotherm was observed again. This indicates that Form E converts to a high temperature melting form, which is not isolatable because it converts back to Form E upon cooling. This indicates that Form E and the high temperature melting form are interconvertibly related, with Form E being more stable at temperatures <122°C. The melting endotherm at 147.4°C does not match the melting of any other form observed in the screen, providing additional evidence of the presence of a new form at elevated temperatures. The XRPD of this new form can be obtained by in situ hot stage XRPD.
[0349] Example 7: Form F and Form G
[0350] By THF / H2O (0.92 / 0.08 v / v A w = 0.2) to obtain Form F. w = 0.4 and 0.6 THF / H2O room temperature slurry, and in THF / H2O (1: 3) temperature cycle, the formation of Form F was also observed. Form F was further characterized by analyzing the wet solid by XRPD. The sample on the XRPD sample holder was covered with 3511 Kapton film to minimize solvent evaporation. A unique pattern different from Form A and Form F was observed, indicating an unstable solvate phase, which was designated as Form G. After ambient drying, Form G converted to Form F. Fig. 7A Shown is a comparison of the XRPD patterns of Form A, Form F, and Form G. The PLM image shows small, birefringent particles of irregular shape. Figure 7B Thermal analysis in showed that the weight loss was 1.85% up to 165.0°C according to TGA, and a broad endotherm starting at 119.5°C and having a peak temperature of 132.4°C was shown. The KF of Form F was obtained, and the result showed that the water content was 0.6%. By comparing the KF and TGA results, it was concluded that Form F may be a THF solvate.
[0351] Example 8: Form K
[0352] Form K was obtained by rapid cooling from an EtOH solution. Formation of Form K was also observed upon slow evaporation, slurrying at 60°C, slow cooling, and polymer-induced crystallization using EtOH. Fig. 8A Shown is a comparison of the XRPD patterns of Form A and Form K. The PLM image shows small birefringent single particles and agglomerates of irregular shape. Figure 8B Thermal analysis in showed a weight loss of 1.35% up to 160.0°C according to TGA and showed two endothermic events starting at 53.6°C and 106.3°C with peak temperatures at 68.7°C and 125.9°C, respectively. Form K was heated to 90°C and cooled back down. The XRPD of the resulting material showed a change in the compared pattern, as shown in Figure 8C As shown, this is due to the heating driving off the water, thereby producing a dehydrated phase. The water content of the solid was measured by KF to be 1.4%. The weight loss in TGA and the water content obtained by KF are complementary, leading to the conclusion that Form K is a hemihydrate.
[0353] Example 9: Form L
[0354] Form L was obtained by rapid cooling of anisole solutions. Form L formation was also observed in slow cooling experiments using anisole. Fig.9A Shown is a comparison of the XRPD patterns of Form A and Form L. The PLM image shows small birefringent primary particles and agglomerates of irregular shape. Fig. 9B Thermal analysis in the 100% mol / l 2 ...
[0355] Example 10: Form M
[0356] Form M was obtained by rapid cooling of the IPAc solution. Fig. 10A Shown is a comparison of the XRPD patterns of Form A and Form M. The PLM image shows small, birefringent particles of irregular shape. Fig. 10BThermal analysis in , showed a weight loss of 13.33% by TGA up to 165.0°C, and showed 2 overlapping endothermic events in the DSC curve, starting at 109°C and with peak temperatures of 116.7°C and 128.2°C, concurrent with the TGA weight loss step. A KF of Form M was obtained, which showed a water content of 0.2%. By comparing the KF and TGA results, it was concluded that Form M is an IPAc solvate, more specifically, a monosolvate, as determined by calculating the API:solvent stoichiometry from the TGA weight loss.
[0357] Example 11: Form N
[0358] Form N was obtained by temperature cycling in CHCl3 / n-heptane (1:3 v / v). Form N formation was also observed in antisolvent addition, room temperature and 60°C slurries, large volume solvent slurries, and reverse antisolvent addition experiments using n-heptane. Fig.11A A comparison of the patterns of Form A and Form N is shown. The PLM image of Form N shows small irregular birefringent particles. Fig. 11B Thermal analysis in 200 % showed a weight loss of 0.46% up to 179.0° C. and exhibited a single endotherm with an onset at 141.9° C. and a peak temperature of 152.1° C. The minimal weight loss observed indicated the absence of an aqueous phase.
[0359] Example 12: Form O
[0360] Form O was obtained only by slow evaporation in MeOH. Fig. 12A Shown is a comparison of the XRPD patterns of Form A and Form O. The PLM image shows crystals with large plate-like morphology. Fig. 12B Thermal analysis in showed a weight loss of 5.11% by TGA up to 160.0°C and exhibited a broad endotherm starting at 107.4°C and peaking at 110.6°C. Due to this method of generating Form O, minimal solid was isolated. An attempt was made to scale up Form O by cooling crystallization and using the remaining solid as seed. This was unsuccessful and KF was not performed on this form. However, the stoichiometry of API:MeOH calculated from the TGA weight loss was shown to be 1:0.99, providing some evidence that Form O is a MeOH monosolvate.
[0361] Example 13: Form Q
[0362] Form Q was obtained by slurrying Form A in n-butanol at 100° C. Form Q formation was also observed in large volume solvent slurries at 100° C. using isobutanol, propylene glycol, ethylene glycol, and n-pentanol. Fig.13AShows a comparison of the XRPD patterns of Form A and Form Q. The PLM image of Form Q shows very small birefringent particles with irregular shapes. Fig. 13B Thermal analysis in Fig. 13B showed a weight loss of 0.63% up to 160.0 °C and showed a single broad endotherm starting at 101.4 °C and peaking at 130.1 °C. The observed minimum weight loss indicates the anhydrous phase.
[0363] Example 14: Serum competition experiment
[0364] Anhydrous:
[0365] A total of six anhydrates were observed, namely Forms A, C, D, E, N, and Q. All anhydrates were thermodynamically evaluated by slurrying all anhydrates in the nonsolvating solvent n-butanol at equal mass ratios at room temperature and 50 °C. At room temperature and 50 °C, all anhydrates were observed to convert to Form C, indicating that it is the most stable anhydrate.
[0366] Hydrate:
[0367] One hydrate (Form K) was observed and found to be a hemihydrate. Form K was thermodynamically evaluated by preparing slurries of Form K and Form C (the most stable anhydrate) at equal mass ratios at different water activities using a nonsolvating solvent. Initially, EtOH / H2O was used, and the results showed that Form K was more stable in the range 0.1 < Aw < 0.9. However, in this experiment, it was found that Form C was more stable at Aw ≥ 0.9. It was suspected that EtOH might form a solvate that favored the formation of Form K, as at higher water activities, the hydrate should be thermodynamically more stable. The numerical values and results used to obtain the critical water activity follow the laws of thermodynamics, and the results obtained from this experiment can be transferred to another solvent / H2O system. Using Forms K and C, additional critical water activity experiments were conducted in acetone / H2O at w A = 0.5 and 0.9. At both of these water activities, conversion to Form C was observed. These results indicate that Form K is not a stable hydrate and that the formation of Form K is influenced by the presence or absence of EtOH.
[0368] Example 15: Scale-up of Form C
[0369] Form C was successfully scaled up to 5 grams. Starting with Form A, approximately 5 grams were weighed and transferred to a 100 mL bottle. 50 mL of EtOH was added to form a suspension and the mixture was magnetically stirred at 65 °C. Once a clear solution was obtained, the solution was slowly cooled to 50 °C. Once the sample reached 50 °C, H2O was added to the solution at a rate of approximately 1 mL / min until the EtOH / H2O ratio (v / v) reached 1:1. The sample was filtered and the wet solids were evenly distributed onto a large weigh boat, breaking up any large clumps. A sample was extracted from the bulk solid for internal baseline characterization. The XRPD of the wet solid confirmed the formation of Form C, as shown in Figure 2. Fig.14 As shown. The PLM image of the material showed a needle-like morphology with some agglomeration. The extracted sample was vacuum dried at 40°C for several hours and then analyzed by TGA / DSC. The TGA results confirmed the anhydrous nature of Form C, and an increase in enthalpy (AH) was observed. The remaining bulk solid was then vacuum dried over a weekend.
[0370] Example 16: Comparison of simulated XRPD and experimental XRPD data
[0371] Liu et al., Functional Selectivity of a Biased Cannabinoid-1 Receptor (CB1R) Antagonist, ACS Pharmacology & Translational Science, 2021 discloses single crystal data for the compound of Formula I, which is incorporated herein by reference in its entirety.
[0372] This single crystal data was matched to the experimental XRPD data and shown to correspond to Form B by simulation. Fig.15 An overlay of simulated and experimental XRPD data for Form B is shown.
[0373] With minor adjustments at low angles (0.1° 2θ), the simulated XRPD pattern shows a close match to the experimentally obtained pattern of Form B. There is a noticeable drift in the peak positions of the two spectra, but when viewed as a group, the peak intensity ratios and relative positions match very well. The CIF states that the single crystal data were collected at 100K, while the XRPD data were collected under ambient conditions. The displacement on the x-axis is due to thermal contraction and expansion and is to be expected with such a large temperature difference. It is noteworthy that the peak pattern maintains such a good similarity to the simulation, inferring that the temperature change causes a nearly uniform change in the unit cell parameters and indicating that no polymorphic transition occurs over this temperature range. In addition to the crystallographic evidence, the single crystal data also indicate that the crystals are a monosolvate of isopropanol and hemihydrate. Although these ratios are inconsistent with those reported for Form B, the identified solvents are consistent.
[0374] Example 17: Other experimental conditions for obtaining Form C
[0375] Form C was obtained by temperature cycling in water:
[0376] - Add 3 g of the compound of Formula I Form A to the flask;
[0377] - Add 10 volumes of water to the flask;
[0378] - Perform temperature cycling from 60°C to 25°C;
[0379] - The mixture was stirred at 25 °C for 4.5 h;
[0380] - The precipitated crystalline solid was filtered and dried at 20-25°C under nitrogen and identified as Form C by XRPD.
[0381] Form C was also obtained by adding water to the ethanol solution:
[0382] - Dissolve 0.5 g of the compound of Formula I Form A in 6 volumes of EtOH at 60°C;
[0383] - Add 2 volumes of water to the mixture;
[0384] - adding 0.5% seed crystals of Form C to the mixture;
[0385] - Stir the mixture at 60°C for 1 h;
[0386] - The mixture was then cooled to 25°C within 4 h;
[0387] - The mixture was then stirred at 25°C for 8 h;
[0388] - The precipitated crystalline solid was filtered and dried at 20-25°C under nitrogen and identified by XRPD as Form C. The yield was 81%.
[0389] Form C was also obtained by adding water to the methanol solution:
[0390] - Dissolve 0.5 g of Form A of the compound of Formula I in 5 volumes of MeOH at 60°C;
[0391] - Add 0.2 times the volume of water to the mixture;
[0392] - adding 0.5% seed crystals of Form C to the mixture;
[0393] - Stir the mixture at 60°C for 1 h;
[0394] - Add 2.3 times the volume of water to the mixture;
[0395] - Stir the mixture at 60°C for 1 h;
[0396] - The mixture was then cooled to 25°C within 4 h;
[0397] - The mixture was then stirred at 25°C for 8 h;
[0398] - The precipitated crystalline solid was filtered and dried at 20-25°C under nitrogen and identified by XRPD as Form C. The yield was 74%.
[0399] Form C was also obtained by adding water to the n-propanol solution:
[0400] - Dissolve 0.5 g of Form A of the compound of Formula I in 10 volumes of n-PrOH at 60°C;
[0401] - Add 3.2 volumes of water to the mixture;
[0402] - adding 0.5% seed crystals of Form C to the mixture;
[0403] - The mixture was stirred at 53 °C for 1 h;
[0404] - Add 1.8 times the volume of water to the mixture;
[0405] - The mixture was stirred at 53°C for 1 h;
[0406] - The mixture was then cooled to 25°C within 4 h;
[0407] - The mixture was then stirred at 25°C for 13h;
[0408] - The precipitated crystalline solid was filtered and dried at 20-25°C under nitrogen and identified by XRPD as Form C. The yield was 82%.
[0409] Form C was also obtained in crystallization experiments on 5 g, 18 g and 115 g scales, starting with dissolving Form A in ethanol at 40°C, adding water, cooling to 25°C, and collecting the crystallized Form C of the compound of Formula I (yield 92%).
[0410] XRPD Peak List
[0411] Form A:
[0412]
[0413]
[0414] Form B:
[0415]
[0416]
[0417]
[0418] Form C:
[0419]
[0420]
[0421] Form D:
[0422]
[0423]
[0424] Form E:
[0425]
[0426]
[0427] Form F:
[0428]
[0429]
[0430] Form G:
[0431] Form H:
[0432]
[0433]
[0434] Form I:
[0435]
[0436]
[0437] Form J:
[0438] Form K:
[0439] Form L:
[0440]
[0441]
[0442] Form M:
[0443] Form N:
[0444] Form O:
[0445] Form P:
[0446]
[0447]
[0448] Form Q:
[0449]
[0450] Although the present invention has been illustrated and described with respect to one or more implementations, equivalent changes and modifications will occur to other persons skilled in the art upon reading and understanding this specification. In addition, although a particular feature of the present invention may be disclosed for only one of several implementations, that feature may be combined with one or more other features of other implementations, which may be necessary and advantageous for any given or specific application.
[0451] Therefore, it should be understood that the embodiments and implementations described herein are for illustrative purposes only, and various modifications or changes based thereon are enlightening to those skilled in the art, and are included in the spirit and scope of the present application and the scope of the appended claims. Any publication, document, patent, patent application or open text mentioned herein should be understood to be incorporated herein by reference as a whole for all purposes.
Claims
1. Compounds of formula I: It is crystalline and exhibits an X-ray powder diffraction (XRPD) pattern having characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 6.46, 15.88, 19.44 and 5.
86.
2. The compound of claim 1, wherein the XRPD pattern further has characteristic peaks expressed in degrees 2θ (±0.2° 2θ) at 7.46, 22.15, and 26.
24.
3. The compound according to claim 1 or 2, wherein the XRPD pattern further has characteristic peaks expressed in degrees 2θ (±0.2° 2θ) at 9.85, 19.07, 22.
77.
4. The compound according to any one of claims 1 to 3, wherein the XRPD pattern further has characteristic peaks expressed in degrees 2θ (±0.2° 2θ) at 3.81, 17.17 and 20.
84.
5. The compound according to any one of claims 1 to 4, wherein the XRPD pattern further has characteristic peaks expressed in degrees 2θ (±0.2° 2θ) at 17.95, 15.43 and 24.
24.
6. Compounds of formula I: It is crystalline, and its differential scanning calorimetry (DSC) thermogram shows an endotherm with an onset at about 157.1 °C.
7. Compounds of formula I: It is crystalline, and its differential scanning calorimetry (DSC) thermogram shows an endotherm with a peak temperature of about 167.9°C.
8. Compounds of formula I: Its X-ray powder diffraction pattern is substantially the same as that shown in Figure 4A-Form C.
9. Compounds of formula I: It is crystalline and exhibits an X-ray powder diffraction (XRPD) pattern having characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 5.89 and 17.
39.
10. The compound of claim 9, wherein the XRPD pattern further has characteristic peaks expressed in degrees 2θ (±0.2° 2θ) at 9.39 and 17.
80.
11. The compound of claim 9 or 10, wherein the XRPD pattern further has a characteristic peak expressed in degrees 2θ (±0.2° 2θ) at 12.
96.
12. The compound according to any one of claims 9 to 11, wherein the XRPD pattern further has a characteristic peak expressed in degrees 2θ (±0.2° 2θ) at 19.
85.
13. The compound according to any one of claims 9 to 12, wherein the XRPD pattern further has a characteristic peak expressed in degrees 2θ (±0.2° 2θ) at 16.
96.
14. Compounds of formula I: It is crystalline, and its differential scanning calorimetry (DSC) thermogram shows an endotherm with an onset at about 152.2°C.
15. Compounds of formula I: It is crystalline, and its differential scanning calorimetry (DSC) thermogram shows an endotherm with a peak temperature of about 162.3°C.
16. Compounds of formula I: Its X-ray powder diffraction pattern is substantially the same as that shown in FIG2A .
17. A compound according to any one of claims 1 to 16 comprising a crystalline form having a purity of 95% or more.
18. The compound according to claim 17, wherein the purity is 99% or higher.
19. The compound of claim 17, wherein the purity is 99.8% or higher.
20. A compound according to any one of claims 1 to 16 which is substantially pure.
21. A pharmaceutical composition comprising a compound according to any one of claims 1 to 20 and a pharmaceutically acceptable carrier or excipient.
22. The pharmaceutical composition according to claim 21, which is formulated as an oral dosage form.
23. The pharmaceutical composition of claim 22, wherein the oral dosage form is a tablet, capsule, lozenge, pastille or granule.
24. The pharmaceutical composition of claim 22, formulated as an oral suspension.
25. Use of a compound according to any one of claims 1 to 20 or a pharmaceutical composition according to any one of claims 21 to 24 for the treatment of a disease or condition selected from the group consisting of obesity (type 1 or type 2), non-alcoholic and alcoholic fatty liver disease (risk factor for insulin resistance), comorbidities of obesity, comorbidities of diabetes, Prader-Willi syndrome (PWS), pro-opiomelanocortin (POMC) deficiency obesity, LepR deficiency obesity, POMC heterozygous deficiency obesity, POMC epigenetic disorders, Bardet-Biedl syndrome, syndrome, dyslipidemia that predisposes to the development of atherosclerotic heart disease, diabetic nephropathy, fibrosis and fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and Hermansky-Pudlak syndrome pulmonary fibrosis (HPS-PF), and gout.
26. The method of claim 25, wherein the comorbidity of obesity is selected from metabolic syndrome, dementia, heart disease, hypertension, gallbladder disease, gastrointestinal disorders, menstrual disorders, degenerative arthritis, venous stasis ulcers, hypoventilation syndrome, sleep apnea, snoring, coronary artery disease, arteriosclerotic disease, pseudotumor cerebri, osteoarthritis, high cholesterol, and increased incidence of malignant tumors of the liver, ovary, cervix, uterus, breast, prostate or gallbladder.
27. Use according to claim 25, wherein the comorbidity of diabetes (eg type 1) is selected from the group consisting of diabetic nephropathy, chronic kidney disease, diabetic retinopathy, and peripheral and autonomic neuropathy.
28. Use according to claim 25, wherein the disease or condition is selected from diabetes (type 1 or type 2), obesity and non-alcoholic fatty liver disease (eg non-alcoholic steatohepatitis).
29. Use of a compound according to any one of claims 1 to 20 or a pharmaceutical composition according to any one of claims 21 to 24 in the preparation of a medicament for treating a disease or condition selected from the group consisting of obesity (type 1 or type 2), non-alcoholic and alcoholic fatty liver disease (risk factor for insulin resistance), comorbidities of obesity, comorbidities of diabetes, Prader-Willi syndrome (PWS), pro-opiomelanocortin (POMC) deficiency obesity, LepR deficiency obesity, POMC heterozygous deficiency obesity, POMC epigenetic disorders, Bardet-Biedl syndrome, syndrome, dyslipidemia that predisposes to the development of atherosclerotic heart disease, diabetic nephropathy, fibrosis and fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and Hermansky-Pudlak syndrome pulmonary fibrosis (HPS-PF), and gout.
30. The method of claim 29, wherein the comorbidity of obesity is selected from metabolic syndrome, dementia, heart disease, hypertension, gallbladder disease, gastrointestinal disorders, menstrual disorders, degenerative arthritis, venous stasis ulcers, hypoventilation syndrome, sleep apnea, snoring, coronary artery disease, arteriosclerotic disease, pseudotumor cerebri, osteoarthritis, high cholesterol, and increased incidence of malignant tumors of the liver, ovary, cervix, uterus, breast, prostate or gallbladder.
31. Use according to claim 29, wherein the comorbidity of diabetes (eg type 1) is selected from the group consisting of diabetic nephropathy, chronic kidney disease, diabetic retinopathy, and peripheral and autonomic neuropathy.
32. Use according to claim 29, wherein the disease or condition is selected from diabetes (type 1 or type 2), obesity and non-alcoholic fatty liver disease (eg non-alcoholic steatohepatitis).
33. A method of treating a disease or condition selected from the group consisting of obesity, diabetes (type 1 or type 2), nonalcoholic and alcoholic fatty liver disease (risk factor for insulin resistance), comorbidities of obesity, comorbidities of diabetes, Prader-Willi syndrome (PWS), proopiomelanocortin (POMC) deficiency obesity, LepR deficiency obesity, POMC heterozygous deficiency obesity, POMC epigenetic disorders, Bardet-Biedl syndrome, syndrome, dyslipidemia that is susceptible to the development of arteriosclerotic heart disease, diabetic nephropathy, fibrosis and fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF) and Hermansky-Pudlak syndrome pulmonary fibrosis (HPS-PF), and gout, the method comprising administering to a subject in need thereof a compound as defined in any one of claims 1 to 20 or a pharmaceutical composition as defined in any one of claims 21 to 24.
34. The method of claim 33, wherein the comorbidity of obesity is selected from metabolic syndrome, dementia, heart disease, hypertension, gallbladder disease, gastrointestinal disorders, menstrual disorders, degenerative arthritis, venous stasis ulcers, hypoventilation syndrome, sleep apnea, snoring, coronary artery disease, arteriosclerotic disease, pseudotumor cerebri, osteoarthritis, high cholesterol, and increased incidence of malignancies of the liver, ovaries, cervix, uterus, breast, prostate, or gallbladder.
35. The method of claim 33, wherein the comorbidity of diabetes (eg, type 1) is selected from diabetic nephropathy, chronic kidney disease, diabetic retinopathy, and peripheral and autonomic neuropathy.
36. The method of claim 33, wherein the disease or condition is selected from diabetes (type 1 or type 2), obesity, and non-alcoholic fatty liver disease (eg, non-alcoholic steatohepatitis).
37. A method for preparing a compound according to any one of claims 1 to 8, wherein include: suspending a first crystalline form of Formula I in water, the first crystalline form exhibiting an X-ray powder diffraction (XRPD) pattern having characteristic peaks expressed in degrees 2θ (± 0.2° 2θ) at 5.89 and 17.39; subjecting the suspension to a temperature cycle between a first temperature and a second temperature lower than the first temperature; and The compound of Formula I was recovered as a second crystalline form exhibiting an XRPD pattern having characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 6.46, 15.88, 19.44 and 5.
86.
38. The method of claim 37, wherein the first temperature is 45°C to 65°C.
39. The method of claim 38, wherein the first temperature is 50°C to 60°C.
40. The method of any one of claims 37 to 39, wherein the second temperature is from 5°C to 35°C.
41. The method of claim 40, wherein the second temperature is 5°C to 25°C.
42. The method of any one of claims 37 to 41, wherein the first temperature is about 60°C and the second temperature is about 25°C.
43. The method according to any one of claims 37 to 42, further comprising: include: The suspension is stirred and maintained at the second temperature.
44. The method of claim 43, wherein the suspension is stirred and maintained at the second temperature for about 1 hour to about 12 hours.
45. The method of claim 43, wherein stirring and maintaining the suspension at the second temperature is performed for about 3 hours to about 6 hours.
46. The method of any one of claims 37 to 45, wherein recovering the compound of formula I as a second crystalline form comprises filtering the suspension.
47. A method for preparing a compound according to any one of claims 1 to 8, wherein include: dissolving the compound of formula I in a solvent selected from methanol, ethanol, n-propanol and isopropanol to obtain a solution; adding water to the solution until solids precipitate; as well as The compound of Formula I was recovered as a crystalline form exhibiting an XRPD pattern having characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 6.46, 15.88, 19.44 and 5.
86.
48. The method of claim 47, wherein the solvent is selected from methanol, ethanol and n-propanol.
49. The method of claim 47, wherein the solvent is ethanol.
50. The method of any one of claims 47 to 49, wherein dissolving the compound of Formula I in a solvent comprises dissolving the compound of Formula I as a crystalline form exhibiting an X-ray powder diffraction (XRPD) pattern having characteristic peaks expressed in degrees 2θ (± 0.2° 2θ) at 5.89 and 17.
39.
51. The method of any one of claims 47 to 50, wherein dissolving the compound of formula I in a solvent is performed at a first temperature between about 30°C and the boiling point of the solvent.
52. The method of claim 51, wherein the first temperature is from about 35°C to about 60°C.
53. The method of claim 50, wherein adding water is performed at the first temperature.
54. The method of claim 50, further comprising cooling the solvent / water mixture to a second temperature that is lower than the first temperature.
55. The method of claim 54, wherein the second temperature is from about 5°C to about 30°C.
56. The method of claim 54, wherein the second temperature is from about 20°C to about 30°C.
57. The method of any one of claims 47 to 56, wherein the solvent:water ratio (by volume) is from about 1:1 to about 3:
1.
58. The method of claim 57, wherein the solvent:water ratio is from about 2:1 to about 3:
1.
59. The method of any one of claims 47 to 58, wherein recovering the compound of formula I comprises filtering and drying the compound of formula I.
60. A method for preparing a compound according to any one of claims 1 to 8, wherein include: providing a slurry of a first crystalline form of Formula I in a solvent selected from water, n-butanol, and a MIBK / n-heptane mixture, the first crystalline form exhibiting an X-ray powder diffraction (XRPD) pattern having characteristic peaks expressed in degrees 2θ (±0.2° 2θ) at 5.89 and 17.39; stirring the slurry; as well as The compound of Formula I was recovered as a crystalline form exhibiting an XRPD pattern having characteristic peaks expressed in degrees 2Θ (± 0.2° 2Θ) at 6.46, 15.88, 19.44 and 5.
86.
61. The method of claim 60, wherein the solvent is water.
62. The method of claim 60, wherein the solvent is a 1:4 (v / v) MIBK:n-heptane mixture.
63. The method of any one of claims 60 to 62, wherein agitating the slurry is performed at a temperature of about 50°C to about 70°C.
64. The method of claim 63, wherein the temperature is from about 55°C to about 65°C.
65. A process according to any one of claims 37 to 64, further comprising adding seed crystals of a compound as defined in any one of claims 1 to 8 to the mixture.
